本帖最后由 老马 于 2013-3-13 13:43 编辑
- V* R* }- l8 [/ t0 A
. i% S! b3 A8 z" ^; Q0 G2 K; H; g健择（吉西他滨）+顺铂+阿瓦斯汀, \( D0 J2 D) T, C9 y1 I
Gemzar +Cisplatin + Avastin( l, @5 U: S* C
http://annonc.oxfordjournals.org/content/21/9/1804.full
( Z5 u' L; t$ M, j: ]0 JOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ( J( L& t: q0 `/ h) A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. / P& A& c/ L j. p% j& }0 d/ x
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. & }3 A3 K+ P* |. C3 Y( m9 U
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 237)
3 ?; o' l- w7 Q |9 u; {' h华为网盘附件：2 ]% D* W- o1 F# N4 [+ Q3 a
【华为网盘】ava.JPG$ a! x5 U: F+ P
|
显身卡
